- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Aurobindo Pharma net profit drops 10 percent to Rs 824 crore in Q1

Mumbai: Aurobindo Pharma Ltd has posted a 10.2 percent year-on-year (YoY) decline in consolidated net profit for the first quarter of FY26, with profits dropping to Rs 824.2 crore from Rs 918.2 crore in the same quarter last year (Q1 FY25), according to the company’s regulatory filing.
Despite the profit decline, the pharmaceutical major revenue increase 4 per cent YoY to Rs 7,868 crore from Rs 7,567 crore in the year-ago period
Operating profit remained largely stable, with EBITDA slipping 1 per cent to Rs 1,603 crore from Rs 1,619.6 crore.
The EBITDA margin narrowed to 20.3 per cent from 21.4 per cent a year ago, the company stated in its regulatory filing.
According to PTI, The US formulations segment, which contributes a significant share of the business, declined 1.9 per cent YoY to Rs 3,488 crore ($408 million), affected by destocking and seasonal factors.
In contrast, the European formulations business saw strong growth of 18 per cent to Rs 2,338 crore (241 million euros).
Revenue from growth markets was up 8.8 per cent at Rs 772 crore ($90 million), while antiretroviral (ARV) sales jumped 55.2 per cent to Rs 355 crore ($41 million).
However, revenue from the active pharmaceutical ingredients (API) segment fell 16 per cent to Rs 916 crore ($107 million), as per its regulatory filing.
The company spent Rs 367 crore on research and development during the quarter, accounting for 4.7 per cent of total revenue.
It received final approval for 14 Abbreviated New Drug Applications (ANDAs) from the US Food and Drug Administration, including one that had earlier received tentative approval.
Vice-Chairman and Managing Director K. Nithyananda Reddy said the company started the year steadily, with strong momentum in the European market and resilience in the US business despite short-term challenges.
He added that disciplined execution, operational initiatives, and a recent US acquisition would help accelerate growth.
Aurobindo Pharma declared an interim dividend of Rs 4 per equity share and set August 8 as the record date.
The dividend will be paid on or before August 21, the company added in its regulatory filing.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.